Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

Description

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Conditions

Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease

Study Overview

Study Details

Study overview

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

Condition
Amyotrophic Lateral Sclerosis
Intervention / Treatment

-

Contacts and Locations

Phoenix

Barrow Neurological Institute, Phoenix, Arizona, United States, 85013

San Diego

University of California San Diego, San Diego, California, United States, 92121

Georgetown

Georgetown University, Georgetown, District of Columbia, United States, 20007

Jacksonville

Mayo Clinic, Jacksonville, Florida, United States, 32224

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Saint Louis

Washington University, Saint Louis, Missouri, United States, 63110

New York

Columbia University, New York, New York, United States, 10032

Houston

Baylor College of Medicine, Houston, Texas, United States, 77030

Seattle

University of Washington, Seattle, Washington, United States, 98195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Target ALS Foundation, Inc.,

    Laura Dugom, MPH, STUDY_DIRECTOR, Target ALS Foundation, Inc.

    Amy Easton, PhD, STUDY_DIRECTOR, Target ALS Foundation, Inc.

    Study Record Dates

    2031-12-31